The Danish C25 company Novonesis, which is the result of a merger between Novozymes and Chr. Hansen, will no longer do business in Russia. The biotech company tells Finans that it has no further comments on the decision.
Novonesis has been in a dilemma regarding its business in Russia in recent months. While Novozymes had pulled the plug on its Russian activities before the merger, Chr. Hansen remained active in the country.
It was therefore up to CEO Ester Baiget to set the future, common line, and she has now come to the conclusion that Novonesis should no longer be present in Russia.
It is not known what will happen to Novonesis' Russian activities and whether a buyer has been found for them. It is also unknown how much lost revenue this will entail.
Chr. However, before the merger, Hansen announced that the profits from the Russian business would in any case be donated to humanitarian aid in Ukraine.
Novonesis produces enzymes and microorganisms for use in a wide range of industries, including the food industry. The merger between the two companies was completed at the beginning of the year. The Novo Nordisk Foundation owns 29 percent of the share capital in Novonesis, but holds 74 percent of the votes.
/ritzau/
Text, graphics, images, sound, and other content on this website are protected under copyright law. DK Medier reserves all rights to the content, including the right to exploit the content for the purpose of text and data mining, cf. Section 11b of the Copyright Act and Article 4 of the DSM Directive.
Customers with IP agreements/major customer agreements may only share Danish Offshore Industry articles internally for the purpose of handling specific cases. Sharing in connection with specific cases refers to journaling, archiving, or similar uses.
Customers with a personal subscription/login may not share Danish Offshore Industry articles with individuals who do not themselves have a personal subscription to Danish Offshore Industry.
Any deviation from the above requires written consent from DK Medier.
